“Long Neuro COVID-19 is hypothesized to follow SARS-CoV-2 virus specific pathophysiological changes, with aberrant inflammatory disease and immune responses post-acute infection, similar to that reported with other viral infections including Epstein-Barr Virus (EBV) and associated Chronic Fatigue Syndrome2. Notably patients who had COVID-19 while also infected with EBV were at an increased risk of memory loss7 and EBV infection increases the risk of autoimmune diseases such as Multiple Sclerosis (MS)8 and associated adverse neurological manifestations. ANP’s immunomodulatory drug ATL1102 has previously demonstrated biologic activity in MS patients…”
Itsa :No brainer..
Ann: Long COVID-19 strategic collaboration with US Experts, page-244
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.7¢ |
Change
0.000(0.00%) |
Mkt cap ! $69.41M | |||
| Open | High | Low | Value | Volume |
| 7.7¢ | 8.0¢ | 7.7¢ | $134.7K | 1.732M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 99278 | 7.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.9¢ | 122500 | 1 |
View Market Depth
| Last trade - 16.10pm 07/05/2024 (20 minute delay) ? |
|
|||||
|
Last
7.7¢ |
Change
0.000 ( 0.00 %) |
||||
| Open | High | Low | Volume | ||
| 7.9¢ | 8.0¢ | 7.7¢ | 70281 | ||
| Last updated 15.51pm 07/05/2024 ? | |||||
| PER (ASX) Chart |